Sonnet BioTherapeutics
SONN
SONN was delisted on the 2nd of December, 2025.
8 hedge funds and large institutions have $216K invested in Sonnet BioTherapeutics in 2025 Q1 according to their latest regulatory filings, with 3 funds opening new positions, 2 increasing their positions, 1 reducing their positions, and 4 closing their positions.
100% more repeat investments, than reductions
Existing positions increased: 2 | Existing positions reduced: 1
66% more capital invested
Capital invested by funds: $130K → $216K (+$85.9K)
2.29% more ownership
Funds ownership: 2.96% → 5.25% (+2.3%)
11% less funds holding
Funds holding: 9 → 8 (-1)
25% less first-time investments, than exits
New positions opened: 3 | Existing positions closed: 4
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
MI
MMCAP International
Grand Cayman,
Cayman Islands
|
+$205K |
| 2 |
Geode Capital Management
Boston,
Massachusetts
|
+$38.1K |
| 3 |
UBS Group
Zurich,
Switzerland
|
+$212 |
| 4 |
Bank of America
Charlotte,
North Carolina
|
+$32 |
| 5 |
Barclays
London,
United Kingdom
|
+$26 |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
VF
Virtu Financial
New York
|
-$58K |
| 2 |
Citadel Advisors
Miami,
Florida
|
-$35.1K |
| 3 |
Two Sigma Investments
New York
|
-$28K |
| 4 |
TRCT
Tower Research Capital (TRC)
New York
|
-$5.4K |
| 5 |
Citigroup
New York
|
-$3 |
SONN Hedge Fund Activity: Q1 2025 in Review
8 of the 7,472 institutional investors tracked by Wall St. Rank reported a position in Sonnet BioTherapeutics (SONN) for Q1 2025, worth a combined $216K — up 66% from $130K a quarter earlier.
Sellers outnumbered buyers: 4 funds closed out of SONN and 3 opened new positions — a net loss of 1 holder — while 1 trimmed existing stakes and 2 added.
The largest buyer was MMCAP International, opening a new position worth an estimated $205K. The largest seller was Virtu Financial, exiting entirely with an estimated $58K sold.
- 8 institutional investors held Sonnet BioTherapeutics (SONN) as of Q1 2025, down from 9 in Q4 2024.
- Funds reported $216K of Sonnet BioTherapeutics stock for Q1 2025, up 66% quarter-over-quarter.
- 3 funds opened new Sonnet BioTherapeutics positions in Q1 2025 and 4 closed out, a net change of -1 holder.
- The largest Sonnet BioTherapeutics buyer in Q1 2025 was MMCAP International, an estimated $205K added.
- The largest Sonnet BioTherapeutics seller in Q1 2025 was Virtu Financial, an estimated $58K sold.
Based on aggregated 13F filings for Q1 2025.